Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05492630
Other study ID # HEC73077-P-01
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date May 24, 2021
Est. completion date January 4, 2023

Study information

Verified date April 2023
Source Sunshine Lake Pharma Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Safety, Tolerability Pharmacokinetic and Food Effect Study of HEC73077 in Healthy Subjects


Recruitment information / eligibility

Status Completed
Enrollment 138
Est. completion date January 4, 2023
Est. primary completion date January 4, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: 1. Sign the informed consent form before the trial and fully understand the contents of the trial, the process and possible adverse reactions. 2. Be able to complete the study according to the trail protocol. 3. Subjects (including partners) have no pregnancy plan within 6 months after the last dose of study drug and voluntarily take effective contraceptive measures. 4. subjects and must be 18 to 45 years of age inclusive. 5. Body weight = 45 kg(for female) or = 50 kg(for male) and body mass index(BMI)between 18 and 28 kg / m^2, inclusive, at screening. 6. There was no clinically significant medical history of respiratory, circulatory, digestive, urinary, blood, endocrine, nervous system diseases and metabolic abnormalities at screening. 7. Subjects, who are healthy, as having no clinically significant abnormalities in vital signs, physical examination, clinical laboratory test results, Chest X-ray and 12-lead electrocardiogram (ECG). Exclusion Criteria: 1. Use of >5 cigarettes per day during the past 3 months. 2. Known history of allergy to study drugs,or allergies constitution ( multiple drug and food allergies). 3. History of alcoholism or drink regularly within 3 months prior to the study (defined as Alcohol consumption of > 14 units/week). 4. Positive results from urine drug screen test. 5. Donation or loss of blood over 450 mL within 3 months prior to screening. 6. Subjects suffering from gastrointestinal diseases that can interfere with absorption or metabolism of drugs within 6 months before screening. 7. Use of any prescription or non-prescription medications within 14 days prior to initial dosing 8. Consume foods or beverages containing caffeine, xanthine, alcohol, and grapefruit within 48 hours prior to initial dosing. 9. Subjects who participated in another clinical trial within 3 months prior to initial dosing. 10. Female subjects were lactating or had positive serum pregnancy results during the screening or testing period. 11. Subjects deemed unsuitable by the investigator for any other reason.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
HEC73077 tablets
Single-Dose Study: Each dose of HEC73077 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight. Multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study.
HEC73077 placebo tablets
Single-Dose Study: Each dose of HEC73077 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight. Multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study.

Locations

Country Name City State
China The First Hospital of Jilin University Changchun Jilin

Sponsors (1)

Lead Sponsor Collaborator
Sunshine Lake Pharma Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse Events Incidence of adverse events Up to 19 days
Primary Cmax Maximum plasma concentration of study drugs Day 1-17
Primary AUC0-8 area under the concentration versus time curve (AUC) from time zero to infinity Day 1-17
See also
  Status Clinical Trial Phase
Recruiting NCT04562025 - Clinical Research of UC-MSCs in the Treatment of Diabetic Nephropathy N/A
Not yet recruiting NCT03658317 - Renal Resisitive Index as an Indicator of the Progression of Diabetic Nephropathy N/A
Recruiting NCT02501772 - The Evaluation of Effect of Sanyinjiao (SP6) Acupressure on Early Diabetic Nephropathy N/A
Completed NCT02251067 - Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients Phase 2
Completed NCT02829177 - Microalbuminuria and Allopurinol in Type 1 Diabetes Phase 4
Completed NCT02276196 - Effect of LIXIsenatide on the Renal System Phase 4
Completed NCT01440257 - A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria Phase 2
Active, not recruiting NCT01273675 - An Investigation on the Effect of Candesartan on Early Diabetic Nephropathy N/A
Terminated NCT01129557 - Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease Phase 4
Completed NCT00317954 - Spironolactone in Diabetic Nephropathy Phase 4
Active, not recruiting NCT02237352 - Mechanisms of Diabetic Nephropathy in Ecuador
Not yet recruiting NCT05061459 - The Expression of circANKRD36 as a New Biomarker of Diabetic Nephropathy
Completed NCT01935167 - To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy Phase 2
Recruiting NCT01673204 - Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Phase 4
Completed NCT01726816 - Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy Phase 2
Recruiting NCT01458158 - Matrix Metalloproteinases in Atherosclerosis of Chronic Kidney Disease N/A
Completed NCT01476501 - Vitamin D Supplementation in Diabetic Nephropathy Phase 2
Completed NCT01447147 - A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy Phase 2
Completed NCT01003236 - Evaluating the Renoprotective Effect of Milk Thistle Extract on Patients With Type II Diabetic Nephropathy Phase 2
Completed NCT00535925 - Nephropathy In Type 2 Diabetes and Cardio-renal Events Phase 4